A metabolic alarmin from keratinocytes potentiates systemic humoral immunity
Article metadata
Article Date: 04 March 2026
Article URL: https://www.nature.com/articles/s41586-026-10167-6
Article Image: (none provided)
Summary
This Nature paper reports that keratinocytes release a mevalonate-pathway metabolite, farnesyl pyrophosphate (FPP), during infection or stress and that FPP functions as a metabolic alarmin to boost systemic humoral immunity. FPP activates the TRPV3 ion channel in keratinocytes, triggering calcium influx and rapid cytokine (notably IL-6 and CCL20) production. Those signals promote dendritic cell migration (via CCR6/CCL20), germinal-centre reactions and stronger antigen-specific IgG responses. Mechanistic work includes LC–MS detection of FPP, single-cell and bulk sequencing, genetic knockouts (including TRPV3 and keratinocyte-specific IL-6 loss), pharmacological modulation (simvastatin, TRPV3 inhibitors), vaccination and infection challenge models (GAS, pneumococcus, influenza). Importantly, while the FPP–TRPV3 axis enhances vaccine responses and protection, hyperactivation can worsen systemic lupus erythematosus (SLE)-like pathology; human SLE skin shows correlated signatures.
Key Points
- Keratinocytes produce and release FPP (a mevalonate-pathway intermediate) in response to infection, UV or ER stress; FPP is detectable in infected skin by LC–MS.
- FPP activates TRPV3 on keratinocytes, causing Ca2+ influx and rapid transcriptional induction of IL-6, CCL20 and other cytokines/chemokines.
- Keratinocyte-derived IL-6 and CCL20 recruit and activate dermal dendritic cells (CCR6-mediated migration) and promote Tfh and GC B cell responses, raising systemic antigen-specific IgG.
- Co-administration of FPP with antigen acts as an adjuvant in multiple vaccine models (OVA, NP-KLH, pneumococcal and influenza subunit vaccines) and improves protection on challenge.
- Genetic or pharmacological disruption of TRPV3 or mevalonate-pathway enzymes (HMGCR/FDPS) blunts FPP generation/signalling and reduces humoral responses; simvastatin lowers FPP and associated cytokines.
- Excessive activation of the FPP–TRPV3 axis exacerbates autoimmunity in mouse SLE models; human SLE epidermis shows elevated TRPV3/CCL20 and mevalonate signatures linking to clinical activity.
- Work combines mouse genetic models, primary keratinocytes, scRNA/scATAC-seq, proteomics/LC–MS, and vaccine/infection challenge experiments to triangulate mechanism and translational relevance.
Content summary
The authors mapped mevalonate-pathway activity in skin and found FPP accumulates in keratinocytes after infection, UV or ER stress. Applied or endogenous FPP activates TRPV3, producing a calcium signal that drives rapid IL-6 and CCL20 release from epidermis. These signals mobilise dermal cDCs into draining lymph nodes, increasing Tfh and germinal-centre B-cell responses and raising systemic IgG titres. FPP acts as an effective adjuvant when co-administered intradermally, improving protection against bacterial and viral challenge in mice. Blockade of TRPV3 or keratinocyte IL-6 eliminates the adjuvant benefit, and blocking the mevalonate pathway (simvastatin) reduces FPP and cytokine output. Conversely, pathological increases in the pathway and TRPV3 activation worsen lupus-like disease in models; patient skin data show concordant changes in SLE, suggesting clinical relevance and potential risk for dysregulation. The work highlights the skin as an immune-modulatory organ that communicates metabolic stress to adaptive immunity via a defined metabolite–ion-channel axis.
Context and relevance
Why it matters: the paper identifies a concrete metabolic molecule (FPP) acting as an alarmin that links epithelial metabolism to systemic antibody responses. That connects two hot topics — immunometabolism and barrier tissue immunology — and suggests new vaccine adjuvant strategies as well as cautionary notes for autoimmune disease mechanisms. TRPV3 and the mevalonate pathway emerge as actionable nodes: TRPV3 as a transducer and HMGCR/FDPS as upstream regulators that can be drugged (statins, small-molecule modulators). The findings are relevant to researchers in vaccinology, immunology, dermatology and autoimmunity, and to translational groups exploring adjuvants or immunomodulators.
Why should I read this?
Short version: skin isn’t just a barrier — it shouts. If you care about how local metabolic stress alters whole-body antibody responses (vaccine design, infection protection, or autoimmune flare-ups), this paper gives you a clear mechanism and lots of usable data. It’s one of those papers where the experiment list reads like a toolkit: LC–MS, scRNA/ATAC, KO mice, vaccine/challenge trials. Read it if you want ideas for adjuvants, targets to tweak humoral immunity, or explanations for skin-driven autoimmunity.
Author style (punchy)
Big, clear finding with real translational teeth — FPP → TRPV3 → keratinocyte cytokines → better antibodies, but too much can harm. If you work on vaccines or autoimmunity, this is a must-read; otherwise, it’s a neat reminder that metabolites can act as danger signals and that the skin is an immune command centre.